Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of “Buy” from Brokerages

Posted by on Jul 26th, 2026

Shares of Immunic, Inc. (NASDAQ:IMUX – Get Free Report) have earned an average rating of “Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $47.5714.

Several brokerages recently commented on IMUX. B. Riley Financial dropped their target price on Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, May 22nd. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Roth Capital reiterated a “buy” rating and set a $19.00 price objective on shares of Immunic in a research note on Thursday, May 14th. Wolfe Research initiated coverage on shares of Immunic in a research report on Friday, May 22nd. They set an “outperform” rating on the stock. Finally, Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Sunday, April 19th.

View Our Latest Research Report on Immunic

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. OMERS ADMINISTRATION Corp acquired a new position in shares of Immunic in the first quarter worth about $187,000. Renaissance Technologies LLC acquired a new stake in Immunic during the 1st quarter valued at approximately $1,020,000. XTX Topco Ltd acquired a new stake in Immunic during the 4th quarter valued at approximately $120,000. Jane Street Group LLC increased its holdings in Immunic by 46.8% during the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock worth $153,000 after purchasing an additional 91,346 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new stake in Immunic during the 3rd quarter worth approximately $29,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Trading Down 6.2%

Shares of NASDAQ IMUX opened at $13.39 on Friday. Immunic has a 12-month low of $5.06 and a 12-month high of $15.84. The company has a market cap of $182.37 million, a P/E ratio of -2.40 and a beta of 1.37. The stock has a fifty day moving average price of $14.13 and a 200 day moving average price of $11.23.

Immunic (NASDAQ:IMUX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37). On average, sell-side analysts forecast that Immunic will post -4.57 EPS for the current fiscal year.

Immunic Company Profile

(Get Free Report)

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.

Featured Stories

Analyst Recommendations for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.